Hence, we first interrogated a genomics database (cBioPortal for Cancer Genomics) and noted that the GOLIM4/GPP130 gene is amplified in up to ~35% of lung cancer patients, ~20% of ovarian cancer patients, ~15% of cervical cancer and in >10% of head-and-neck cancer patients (Figure 1B). This evidence concerns the gene GOLIM4 and ovarian cancer.